Pure Global

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC) - Trial NCT06082635

Access comprehensive clinical trial information for NCT06082635 through Pure Global AI's free database. This Phase 3 trial is sponsored by Shenzhen TargetRx, Inc. and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 297 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06082635
Phase 3
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06082635
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
A Multi-centered, Randomized, Open-label Phase III Study to Evaluate the Efficacy and Safety of TGRX-326 Comparing With Crizotinib in Patients of Advanced ALK-positive or Metastatic Non-Small Cell Lung Cancer

Study Focus

TGRX-326

Interventional

drug

Sponsor & Location

Shenzhen TargetRx, Inc.

Timeline & Enrollment

Phase 3

Nov 30, 2023

Nov 30, 2028

297 participants

Primary Outcome

Progression Free Survival (PFS) by independent review committee (IRC)

Summary

This is a multi-center, randomized, open-label, Phase III clinical trial which compares the
 safety and efficacy of TGRX-326 with crizotinib in patients with ALK-positive advanced or
 metastatic NSCLC

ICD-10 Classifications

Secondary malignant neoplasm of lung
Malignant neoplasm: Lower lobe, bronchus or lung
Malignant neoplasm: Middle lobe, bronchus or lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm of bronchus and lung

Data Source

ClinicalTrials.gov

NCT06082635

Non-Device Trial